Patents Assigned to Archimedes Development Limited
  • Publication number: 20100256091
    Abstract: A powder composition for intranasal delivery includes a benzodiazepine drug and chitosan, a salt of chitosan, a derivative of chitosan or a salt of a derivative of chitosan.
    Type: Application
    Filed: August 29, 2008
    Publication date: October 7, 2010
    Applicant: ARCHIMEDES DEVELOPMENT LIMITED
    Inventors: Peter James Watts, Yu-Hui Cheng, Alan Smith, Jonathan Castile
  • Publication number: 20100249170
    Abstract: A liquid aqueous formulation for the intranasal administration of apomorphine includes: (a) at least about 15 mg/ml of apomorphine; and (b) a solubilising agent selected from (i) at least one polyoxyethylene-polyoxypropylene copolymer (poloxamer); (ii) at least one cyclodextrin; and (iii) at least one cyclodextrin together with chitosan. The formulations of the invention can be used in the treatment or management of Parkinson's disease and erectile dysfunction.
    Type: Application
    Filed: November 10, 2008
    Publication date: September 30, 2010
    Applicant: ARCHIMEDES DEVELOPMENT LIMITED
    Inventors: Peter Watts, Yu-Hui Cheng
  • Publication number: 20100203119
    Abstract: The present invention provides a solid composition for oral administration comprising: (i) a drug compound; (ii) chitosan or a derivative thereof or a salt of chitosan or salt of a derivative of chitosan; and (iii) an organic acid. Preferably the drug compound is a polar molecule having a molecular weight of 1 KDa or less, a peptide, a protein or a polysaccharide. The compositions of the invention provide enhance absorption of the drug compound.
    Type: Application
    Filed: April 23, 2010
    Publication date: August 12, 2010
    Applicant: ARCHIMEDES DEVELOPMENT LIMITED
    Inventors: Michael LEANE, Alan SMITH, Lisbeth ILLUM
  • Patent number: 7666876
    Abstract: Aqueous formulations suitable for intranasal administration comprise buprenorphine or a physiologically acceptable salt or ester thereof and (a) a pectin having a degree of esterification of less than 50%, (b) chitosan and a polyoxyethylene-polyoxypropylene copolymer (poloxamer) or (c) chitosan and hydroxypropylmethylcellulose. Such formulations can induce rapid and prolonged analgesia when delivered intranasally to a patient. The buprenorphine or buprenorphine salt or ester may be delivered to the bloodstream to produce within 30 minutes a therapeutic plasma concentration of buprenorphine, Cther, of 0.2 ng/ml or greater which is maintained for a duration Tmaint of at least 2 hours.
    Type: Grant
    Filed: March 19, 2002
    Date of Patent: February 23, 2010
    Assignees: Vernalis (R&D) Limited, Archimedes Development Limited
    Inventors: Phillip John Birch, Ann Gail Hayes, Peter James Watts, Jonathan David Castile
  • Publication number: 20100041624
    Abstract: Aqueous formulations suitable for intranasal administration comprise buprenorphine or a physiologically acceptable salt or ester thereof and (a) a pectin having a degree of esterification of less than 50%, (b) chitosan and a polyoxyethylene-poly-oxypropylene copolymer (poloxamer) or (c) chitosan and hydroxypropylmethylcellulose. Such formulations can induce rapid and prolonged analgesia when delivered intranasally to a patient. The buprenorphine or buprenorphine salt or ester may be delivered to the bloodstream to produce within 30 minutes a therapeutic plasma concentration of buprenorphine, Cther, of 0.2 ng/ml or greater which is maintained for a duration Tmaint of at least 2 hours.
    Type: Application
    Filed: October 19, 2009
    Publication date: February 18, 2010
    Applicants: VERNALIS (R&D) LIMITED, ARCHIMEDES DEVELOPMENT LIMITED
    Inventors: Phillip John Brich, Ann Gail Hayes, Peter James Watts, Jonathan David Castile
  • Patent number: 7662403
    Abstract: There is provided a powder formulation for nasal delivery including a protein having a molecular weight of 10 kDa or greater and chitosan or a derivative thereof or a salt of chitosan or a salt of a derivative of chitosan. Preferably the protein is human growth hormone.
    Type: Grant
    Filed: January 4, 2006
    Date of Patent: February 16, 2010
    Assignee: Archimedes Development Limited
    Inventors: Ann Margaret Dyer, Peter James Watts, Yu-Hui Cheng, Alan Smith
  • Publication number: 20100021553
    Abstract: There is provided a powder formulation for nasal delivery including a protein having a molecular weight of 10 kDa or greater and chitosan or a derivative thereof or a salt of chitosan or a salt of a derivative of chitosan. Preferably the protein is human growth hormone.
    Type: Application
    Filed: September 30, 2009
    Publication date: January 28, 2010
    Applicant: ARCHIMEDES DEVELOPMENT LIMITED
    Inventors: Ann Margaret DYER, Peter James WATTS, Yu-Hui CHENG, Alan SMITH
  • Publication number: 20090233912
    Abstract: A composition for intranasal delivery of a drug comprising: includes: (i) the drug; and (ii) a non-aqueous vehicle containing (a) propylene glycol and at least one additional solvent selected from N-methylpyrrolidone, propylene carbonate, dimethyl sulfoxide and at least one propylene glycol fatty acid ester; (b) from about 40 to 100% by volume of N-methylpyrrolidone; or (c) from about 40 to 100% by volume of dimethyl sulfoxide (DMSO).
    Type: Application
    Filed: August 29, 2008
    Publication date: September 17, 2009
    Applicant: ARCHIMEDES DEVELOPMENT LIMITED
    Inventors: Jonathan CASTILE, Alan SMITH, Yu-Hui CHENG, Peter James WATTS
  • Publication number: 20090130202
    Abstract: Sustained release pharmaceutical compositions contain a drug; microcrystalline cellulose; a diluent (such as starch); a glidant (such as talc); and one or more of ethylcellulose, stearic acid and a salt of stearic acid. Preferred drugs include those that exhibit a low degree of solubility combined with a high potency, particularly thyroid hormones, such as liothyronine.
    Type: Application
    Filed: December 15, 2006
    Publication date: May 21, 2009
    Applicant: ARCHIMEDES DEVELOPMENT LIMITED
    Inventors: Alan Smith, Ann Margaret Dyer
  • Publication number: 20080248991
    Abstract: The invention provides a composition comprising (i) chitosan, a salt or derivative thereof or a salt of a derivative thereof, (ii) a polyol-phosphate or sugar-phosphate salt, (iii) a plasticizer, and (iv) a therapeutic agent. Typically, the composition is a solution or suspension at ambient temperature but forms a gel at physiological temperatures.
    Type: Application
    Filed: February 18, 2005
    Publication date: October 9, 2008
    Applicant: ARCHIMEDES DEVELOPMENT LIMITED
    Inventors: Ann Margaret Dyer, Patricia Pastor, Lisbeth Illum
  • Publication number: 20080153879
    Abstract: A composition for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof to an animal includes an aqueous solution of fentanyl or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive selected from (i) a pectin and (ii)a poloxamer and chitosan or a salt or derivative thereof; provided that when the composition comprises a pectin it is substantially free of divalent metal ions; and which, in comparison to a simple aqueous solution of fentanyl administered intranasally at the same dose, provides a peak plasma concentration of fentanyl (Cmax) that is from 10 to 80% of that achieved using a simple aqueous solution of fentanyl administered intranasally at an identical fentanyl dose. A method for treating or managing pain by intranasally administering the composition is also disclosed.
    Type: Application
    Filed: March 13, 2008
    Publication date: June 26, 2008
    Applicant: ARCHIMEDES DEVELOPMENT LIMITED
    Inventors: Peter James Watts, Jonathan David Castile, William Columbus Ian Lafferty, Alan Smith
  • Patent number: 7323183
    Abstract: There is provided vaccine compositions for intranasal administration, which compositions comprise one or more antigens and an effective adjuvant amount of a chitosan.
    Type: Grant
    Filed: May 8, 2002
    Date of Patent: January 29, 2008
    Assignee: Archimedes Development Limited
    Inventors: Lisbeth Illum, Steven Neville Chatfield
  • Publication number: 20070231269
    Abstract: An analgesic and a delivery agent are combined in a pharmaceutical composition such that, on introduction into the nasal cavity of a patient to be treated, the analgesic may be delivered to the bloodstream to produce within 30 minutes a therapeutic plasma concentration, Cther, of 0.2 ng/ml or greater which is maintained for a duration Tmaint of at least 2 hours. The analgesic may be an opioid analgesic or a non-steroidal anti-inflammatory drug.
    Type: Application
    Filed: May 14, 2007
    Publication date: October 4, 2007
    Applicants: IONIX PHARMACEUTICALS LIMITED, ARCHIMEDES DEVELOPMENT LIMITED
    Inventors: Phillip Birch, Ann Hayes, Peter Watts, Jonathan Castile
  • Publication number: 20070140981
    Abstract: The present invention provides compositions for the intranasal administration of zolpidem or a pharmaceutically acceptable salt thereof. Preferred compositions of the invention are in the form of aqueous solutions. Optionally the compositions of the invention comprise a cyclodextrin and/or chitosan, a salt or derivative thereof or a salt of a derivative of chitosan. The compositions can be used for the treatment or prevention insomnia or the treatment of neurological disorders such as those arising from brain trauma, stroke and spinocerebellar ataxia or in the treatment of Parkinson's disease.
    Type: Application
    Filed: December 23, 2004
    Publication date: June 21, 2007
    Applicant: ARCHIMEDES DEVELOPMENT LIMITED
    Inventors: Jonathan Castile, Yu-Hui Cheng, Paul Jenkins, Alan Smith, Peter Watts
  • Publication number: 20070110677
    Abstract: Liquid pharmaceutical compositions for administration to a mucosal surface, including fentanyl and a pectin with a low degree of esterification are described. Such compositions gel, or can be adapted to gel, at the site of application in the absence of an extraneous source of divalent metal ions.
    Type: Application
    Filed: November 21, 2006
    Publication date: May 17, 2007
    Applicant: ARCHIMEDES DEVELOPMENT LIMITED
    Inventors: Peter Watts, Lisbeth Illum
  • Publication number: 20070092535
    Abstract: Liquid pharmaceutical compositions for administration to a mucosal surface, including a therapeutic agent and a pectin with a low degree of esterification are described. Such compositions gel, or can be adapted to gel, at the site of application in the absence of an extraneous source of divalent metal ions.
    Type: Application
    Filed: November 21, 2006
    Publication date: April 26, 2007
    Applicant: ARCHIMEDES DEVELOPMENT LIMITED
    Inventors: Peter Watts, Lisbeth Illum